Clinical Trials Logo

Clinical Trial Summary

There is a consensus that exercise therapy should be used as a therapy approach in CLBP but little consensus has been reached about the preferential type of therapy. There occurs to be a wash out effect because of the heterogeneous character of CLBP patients. As a result, no effect can be demonstrated for the entire sample. This is why one should consider creating subgroups based on prognostic indicators.

Objectives for this trial is to possibly identify prognostic indicators for treatment response to three forms of exercise therapy for patients with nonspecific chronic low back pain (CLBP).

The study design is a multicenter cohort design. Patients with nonspecific low back pain of more than three months duration are recruited in two different hospitals (Antwerp University Hospital and Sint Vincentius Hospital). After examination patients are assigned to one of three intervention groups: motor control therapy, isometric training therapy and a combination therapy. All patients will undergo eighteen treatment sessions during nine weeks. Measurements will be taken at baseline and after nine weeks of treatment.

The primary outcome used is the Modified Oswestry Disability Questionnaire (MDQ). For each type of exercise therapy prognostic indicators will be investigated.

Never before a multi-arm design was performed for the identification of prognostic indicators for exercise therapy in patients with nonspecific CLBP.


Clinical Trial Description

Methods/ Design

Ethical approval (B300201215600) was obtained from the local ethics committees of the Antwerp University Hospital.

Study design In the identification of prognostic indicators is derived from a number of variables that have predictive potential for therapy outcome. These variables are obtained from baseline measurements and have a multidimensional character (impairments, activities/participation and contextual factors).

Patient recruitment Patients will be recruited by doctors at the service of two settings located in Antwerp namely the Antwerp University Hospital (UZA) and the Sint-Vincentius Hospital. Treatment and measurements will be performed at the site where the patient has been recruited.

Inclusion criteria: Current nonspecific LBP persisting at least three months, consulted a medical doctor during the last month because of the persistent low back pain, age between 18 and 60, sufficient fluency in Dutch to follow treatment instructions and answer survey questions.

Exclusion criteria: spinal canal stenosis, spondylolisthesis and spondylitis, large herniated disc sciatica, radiating pain below the knee, previous back surgery, a history of known spinal fractures, malignancy, known muscle-, nerve-, skin-, or joint diseases, pregnancy and lack of consent.

Measurements

Baseline testing As primary (dependent) outcome measure the Modified Oswestry Disability Questionnaire is used (MDQ). The MDQ is a disease specific questionnaire to measure disability in LBP patients [21-23].

As secondary (independent) outcome measures the following tests are used:

First, Measurement of impairments: duration of the LBP/ pelvis impairments / respiratory impairments (all three items through anamnesis). Prone instability test, Straight Leg Raise, Beighton scale, Active Straight Leg Raise, sitting knee extension test, waiters bow, pelvic tilt, side support test, extensor endurance test, active sit-up, Visual Analogue Scale for pain (VAS).

Second, measurement of limitations in activities and participation: hours of physical activity/week (trough anamnesis). Short Form 36 Health Survey (SF36), Roland Morris Disability Questionnaire (RMDQ).

Third, measurement of contextual factors: gender/ age / height / weight / body mass index / smoking / profession / underwent previous therapy / comorbidity (trough anamnesis). Tampa scale for kinesiophobia, Fear Avoidance Belief Questionnaire (FABQ), We performed a literature search to select all used clinical tests based on their reliability and validity [24]. The Baseline testing takes about 30 minutes.

Follow-up

Follow up takes place after completion of the treatment program at nine weeks. All patient reported outcome measures (PROMs) from the baseline testing will be re-evaluated at this moment.

Randomization & blinding

In the Sint-Vincentius Hospital, all included patients will follow the combination treatment since this is the only intervention group which is being organized in this hospital.

In the UZA, patients will be randomly assigned into one of the two treatment groups (motor control or isometric training) after baseline testing. The responsible researcher will use a randomization list generated with Microsoft ® Excel ® software (version 14.3.9, 2010 © Microsoft Corporation).

Intervention

During the nine weeks intervention, patients will be treated two times a week. Patients will be assigned randomly into one of three intervention groups (motor control therapy, isometric training therapy or combination therapy). Each intervention will take about seventy minutes. Ten minutes warming up and cooling down will be the same in each treatment regime. Each group receives fifty minutes of therapy specific intervention. Previously trained physiotherapists will give the treatment. To ensure that all therapists provide the same exercises, a treatment protocol for each treatment group was developed and a treatment diary will be filled out after each session.

Interventions in derivation and validation phase are similar.

Power analysis

This study describes the identification of prognostic indicators in which the therapeutic effect of the interventions cannot be predicted. Therefore, a two-tailed hypothesis was used to calculate the power. A pilot study showed that the standard deviation of the primary outcome measure, MDQ, is set at 10.53.6 Given these estimates, 54 patients were needed to detect a minimum clinically important difference (MCID, effect size 0.84) with 90% power. Consequently, three groups of 18 patients were needed to complete the trial.

Data analysis

Prognostic indicators aim to detect potential predictive variables for treatment success (dichotomous, yes/no) in a set of baseline measurements. A minimal decrease in the MDQ score of 9 points is considered as treatment success.

Potential predictive variables are selected as follows: first, individual variables from the self-reports, history, and physical examination are tested for their bivariate association with the reference standard using independent sample t tests, Mann-Whitney U tests or Chi-square tests based on the nature of the data. Variables with a significance level of P < 0.10 are retained as potential prediction variables. We choose a more liberal significance level at this stage to avoid excluding potential predictive variables.

This statistical analysis is performed for each treatment group (motor control therapy, general active exercise therapy and isometric training therapy).

Information form and informed consent

If patients meet the in- and exclusion criteria they are scheduled for an interview with one of our researchers to be informed about the trial. If patients decide to participate they will sign an informed consent. Information form and informed consent are made and have been approved by the ethics committee of the University of Antwerp. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02063503
Study type Interventional
Source Universiteit Antwerpen
Contact Lenie Denteneer, phd student
Phone 0032494884189
Email lenie.denteneer@uantwerpen.be
Status Recruiting
Phase N/A
Start date September 2013
Completion date December 2017

See also
  Status Clinical Trial Phase
Completed NCT03243084 - Transcranial Alternating Current Stimulation in Back Pain- Pilot Sudy N/A
Suspended NCT04735185 - Stem Cells vs. Steroids for Discogenic Back Pain N/A
Completed NCT03162952 - RAND Center of Excellence for the Study of Appropriateness of Care in CAM
Completed NCT03240146 - Pulsed Shortwave Therapy Treatment for Chronic Musculoskeletal Low Back Pain N/A
Completed NCT05282589 - Lumbopelvic Manipulation Effects on Fatigue in Chronic Low Back Pain Patients N/A
Completed NCT03637998 - Physical Activity on Neurophysiologic Gene Expression Profiles of Chronic Low Back Pain N/A
Recruiting NCT02289170 - Clinical Study to Evaluate the Safety and Efficacy of Heating and Cooling Combination Therapeutic Device(OCH-S100) N/A
Active, not recruiting NCT01944163 - The IMPACT of a Referral Model for Axial Spondyloarthritis in Young Patients With Chronic Low Back Pain N/A
Completed NCT02231554 - Feldenkrais vs Back School for Treating Chronic Low Back Pain: a Randomized Controlled Trial N/A
Completed NCT01704677 - Lumbar Disc Prosthesis Versus Multidisciplinary Rehabilitation; 8-year Follow-up N/A
Terminated NCT01620775 - MR(Magnetic Resonance) Imaging of Neurotransmitters in Chronic Pain N/A
Completed NCT01177280 - Prevalence of Potential Cytochrome P450 Pharmacokinetic Incident Drug-Drug Interactions Among Chronic Low Back Pain Patients Taking Opioid Analgesics and Associated Economic Outcomes N/A
Completed NCT01177241 - Cytochrome P450 Pharmacokinetic DDIs Among Patients With Chronic Low Back Pain Taking Opioids N/A
Completed NCT01490905 - A Double Blind Placebo Study to Determine the Effectiveness of Theramine on the Management of Chronic Back Pain Phase 4
Completed NCT01177254 - Exposure to Potential Cytochrome P450 Pharmacokinetic Drug-Drug Interactions Among Osteoarthritis Patients: Incremental Risk of Multiple Prescriptions N/A
Completed NCT00984815 - Safety Study of HZT-501 in Patients Who Require Long-Term Daily Non-steroidal Anti-inflammatory Drug Treatment Phase 3
Completed NCT00767806 - A Study for Patient With Chronic Low Back Pain Phase 3
Completed NCT00763321 - Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP) Phase 3
Completed NCT00761150 - Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP) Phase 3
Completed NCT00613106 - Double-Blind Follow-on Safety Study of HZT-501 (Ibuprofen 800 mg/Famotidine 26.6 mg) in Subjects Who Have Completed Participation in HZ-CA-301 (NCT00450658) or HZ-CA-303 (NCT00450216) Phase 3